Publicaciones en colaboración con investigadores/as de Copenhagen University Hospital (10)

2024

  1. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

2020

  1. Effect of platelet storage duration on clinical outcomes and incremental platelet change in critically ill children

    Transfusion, Vol. 60, Núm. 12, pp. 2849-2858

2019

  1. Takotsubo syndrome: State-of-the-art review by an expert panel – Part 1

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 1, pp. 70-79

  2. Takotsubo syndrome: State-of-the-art review by an expert panel – Part 2

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 2, pp. 153-166

2018

  1. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. The SafeBoosC phase II clinical trial: An analysis of the interventions related with the oximeter readings

    Archives of Disease in Childhood: Fetal and Neonatal Edition, Vol. 101, Núm. 4, pp. F333-F338

2012

  1. Gender and survival in patients with heart failure: Interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis

    European Journal of Heart Failure, Vol. 14, Núm. 5, pp. 473-479

2009

  1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

    Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228